Patents by Inventor Henry F. Edelhauser
Henry F. Edelhauser has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220280341Abstract: A microneedle has a proximal end portion and a distal end portion and defines a lumen. The proximal end portion is configured to be coupled to a cartridge to place the lumen in fluid communication with the cartridge. The proximal end portion includes a base surface that is configured to be placed in contact with a surface of a target tissue. The distal end portion of the microneedle includes a beveled surface. The beveled surface defines a tip angle of less than about 20 degrees and a ratio of a bevel height to a bevel width of less than about 2.5.Type: ApplicationFiled: December 10, 2021Publication date: September 8, 2022Inventors: Mark A Prausnitz, Henry F. Edelhauser, Vladimir G. Zarnitsyn, Samirkumar R. Patel, Hans Grossniklaus
-
Publication number: 20210393436Abstract: Methods and devices are provided for targeted administration of a drug to a patient's eye. In one embodiment, the method includes inserting a hollow microneedle into the sclera of the eye at an insertion site and infusing a fluid drug formulation through the inserted microneedle and into the suprachoroidal space of the eye, wherein the infused fluid drug formulation flows within the suprachoroidal space away from the insertion site during the infusion. The fluid drug formulation may flow circumferentially toward the retinochoroidal tissue, macula, and optic nerve in the posterior segment of the eye.Type: ApplicationFiled: January 4, 2021Publication date: December 23, 2021Inventors: Mark R. Prausnitz, Henry F. Edelhauser, Samirkumar Rajnikant Patel
-
Patent number: 10905586Abstract: Methods and devices are provided for targeted administration of a drug to a patient's eye. In one embodiment, the method includes inserting a hollow microneedle into the sclera of the eye at an insertion site and infusing a fluid drug formulation through the inserted microneedle and into the suprachoroidal space of the eye, wherein the infused fluid drug formulation flows within the suprachoroidal space away from the insertion site during the infusion. The fluid drug formulation may flow circumferentially toward the retinochoroidal tissue, macula, and optic nerve in the posterior segment of the eye.Type: GrantFiled: March 23, 2020Date of Patent: February 2, 2021Assignees: Georgia Tech Research Corporation, Emory UniversityInventors: Mark Prausnitz, Henry F. Edelhauser, Samirkumar Rajnikant Patel
-
Publication number: 20210022918Abstract: Methods and devices are provided for targeted administration of a drug to a patient's eye. In one embodiment, the method includes inserting a hollow microneedle into the sclera of the eye at an insertion site and infusing a fluid drug formulation through the inserted microneedle and into the suprachoroidal space of the eye, wherein the infused fluid drug formulation flows within the suprachoroidal space away from the insertion site during the infusion. The fluid drug formulation may flow circumferentially toward the retinochoroidal tissue, macula, and optic nerve in the posterior segment of the eye.Type: ApplicationFiled: October 2, 2020Publication date: January 28, 2021Inventors: Mark R. Prausnitz, Henry F. Edelhauser, Samirkumar Rajnikant Patel
-
Publication number: 20200237556Abstract: Methods and devices are provided for targeted administration of a drug to a patient's eye. In one embodiment, the method includes inserting a hollow microneedle into the sclera of the eye at an insertion site and infusing a fluid drug formulation through the inserted microneedle and into the suprachoroidal space of the eye, wherein the infused fluid drug formulation flows within the suprachoroidal space away from the insertion site during the infusion. The fluid drug formulation may flow circumferentially toward the retinochoroidal tissue, macula, and optic nerve in the posterior segment of the eye.Type: ApplicationFiled: March 23, 2020Publication date: July 30, 2020Inventors: Mark Prausnitz, Henry F. Edelhauser, Samirkumar Rajnikant Patel
-
Patent number: 10632013Abstract: Methods and devices are provided for targeted administration of a drug to a patient's eye. In one embodiment, the method includes inserting a hollow microneedle into the sclera of the eye at an insertion site and infusing a fluid drug formulation through the inserted microneedle and into the suprachoroidal space of the eye, wherein the infused fluid drug formulation flows within the suprachoroidal space away from the insertion site during the infusion. The fluid drug formulation may flow circumferentially toward the retinochoroidal tissue, macula, and optic nerve in the posterior segment of the eye.Type: GrantFiled: September 19, 2017Date of Patent: April 28, 2020Assignees: GEORGIA TECH RESEARCH CORPORATION, EMORY UNIVERSITYInventors: Mark R. Prausnitz, Henry F. Edelhauser, Samirkumar Rajnikant Patel
-
Publication number: 20180028357Abstract: Methods and devices are provided for targeted administration of a drug to a patient's eye. In one embodiment, the method includes inserting a hollow microneedle into the sclera of the eye at an insertion site and infusing a fluid drug formulation through the inserted microneedle and into the suprachoroidal space of the eye, wherein the infused fluid drug formulation flows within the suprachoroidal space away from the insertion site during the infusion. The fluid drug formulation may flow circumferentially toward the retinochoroidal tissue, macula, and optic nerve in the posterior segment of the eye.Type: ApplicationFiled: September 19, 2017Publication date: February 1, 2018Inventors: Mark R. Prausnitz, Henry F. Edelhauser, Samirkumar Rajnikant Patel
-
Patent number: 9788995Abstract: Methods and devices are provided for targeted administration of a drug to a patient's eye. In one embodiment, the method includes inserting a hollow microneedle into the sclera of the eye at an insertion site and infusing a fluid drug formulation through the inserted microneedle and into the suprachoroidal space of the eye, wherein the infused fluid drug formulation flows within the suprachoroidal space away from the insertion site during the infusion. The fluid drug formulation may flow circumferentially toward the retinochoroidal tissue, macula, and optic nerve in the posterior segment of the eye.Type: GrantFiled: December 20, 2013Date of Patent: October 17, 2017Assignees: Georgia Tech Research Corporation, Emory UniversityInventors: Mark R. Prausnitz, Henry F. Edelhauser, Samirkumar Rajnikant Patel
-
Publication number: 20170273827Abstract: A microneedle has a proximal end portion and a distal end portion and defines a lumen. The proximal end portion is configured to be coupled to a cartridge to place the lumen in fluid communication with the cartridge. The proximal end portion includes a base surface that is configured to be placed in contact with a surface of a target tissue. The distal end portion of the microneedle includes a beveled surface. The beveled surface defines a tip angle of less than about 20 degrees and a ratio of a bevel height to a bevel width of less than about 2.5.Type: ApplicationFiled: June 9, 2017Publication date: September 28, 2017Inventors: Mark R. Prausnitz, Henry F. Edelhauser, Vladimir G. Zarnitsyn, Samirkumar R. Patel, Hans Grossniklaus
-
Publication number: 20160310417Abstract: Formulations, systems, and methods of administration are provided for preferential targeted delivery of drug to ocular tissue. In embodiments, the formulation may include a non-Newtonian fluid that facilitates targeted localization or preferential spreading of the fluid formulation in the ocular tissue. The fluid formulation may be administered to an eye of a patient by inserting a microneedle into the eye at an insertion site, and infusing a volume of a fluid formulation through the microneedle into the suprachoroidal space of the eye at the insertion site over a first period. During the first period, the fluid formulation may be distributed over a first region which is less than about 10% of the suprachoroidal space, and during the second period subsequent to the first period the drug formulation may be distributed over a second region which is greater than about 20% of the suprachoroidal space.Type: ApplicationFiled: December 19, 2014Publication date: October 27, 2016Inventors: Mark R. PRAUSNITZ, Yoo Chun KIM, Henry F. EDELHAUSER
-
Publication number: 20150209180Abstract: A microneedle has a proximal end portion and a distal end portion and defines a lumen. The proximal end portion is configured to be coupled to a cartridge to place the lumen in fluid communication with the cartridge. The proximal end portion includes a base surface that is configured to be placed in contact with a surface of a target tissue. The distal end portion of the microneedle includes a beveled surface. The beveled surface defines a tip angle of less than about 20 degrees and a ratio of a bevel height to a bevel width of less than about 2.5.Type: ApplicationFiled: August 27, 2013Publication date: July 30, 2015Applicant: Clearside Biomedical, Inc.Inventors: Mark R. Prausnitz, Henry F. Edelhauser, Vladimir G. Zarnitsyn, Samirkumar R. Patel, Hans Grossniklaus
-
Patent number: 8808225Abstract: Methods and devices are provided for targeted administration of a drug to a patient's eye. In one embodiment, the method includes inserting a hollow microneedle into the sclera of the eye at an insertion site and infusing a fluid drug formulation through the inserted microneedle and into the suprachoroidal space of the eye, wherein the infused fluid drug formulation flows within the suprachoroidal space away from the insertion site during the infusion. The fluid drug formulation may flow circumferentially toward the retinochoroidal tissue, macula, and optic nerve in the posterior segment of the eye.Type: GrantFiled: April 15, 2012Date of Patent: August 19, 2014Assignees: Emory University, Georgia Tech Research CorporationInventors: Mark R. Prausnitz, Henry F. Edelhauser, Samirkumar Rajnikant Patel
-
Publication number: 20140107566Abstract: Methods and devices are provided for targeted administration of a drug to a patient's eye. In one embodiment, the method includes inserting a hollow microneedle into the sclera of the eye at an insertion site and infusing a fluid drug formulation through the inserted microneedle and into the suprachoroidal space of the eye, wherein the infused fluid drug formulation flows within the suprachoroidal space away from the insertion site during the infusion. The fluid drug formulation may flow circumferentially toward the retinochoroidal tissue, macula, and optic nerve in the posterior segment of the eye.Type: ApplicationFiled: December 20, 2013Publication date: April 17, 2014Applicants: Georgia Tech Research Corporation, Emory UniveristyInventors: Mark R. Prausnitz, Henry F. Edelhauser, Samirkumar Rajnikant Patel
-
Patent number: 8636713Abstract: Methods and devices are provided for targeted administration of a drug to a patient's eye. In one embodiment, the method includes inserting a hollow microneedle into the sclera of the eye at an insertion site and infusing a fluid drug formulation through the inserted microneedle and into the suprachoroidal space of the eye, wherein the infused fluid drug formulation flows within the suprachoroidal space away from the insertion site during the infusion. The fluid drug formulation may flow circumferentially toward the retinochoroidal tissue, macula, and optic nerve in the posterior segment of the eye.Type: GrantFiled: April 23, 2012Date of Patent: January 28, 2014Assignees: Emory University, Georgia Tech Research CorporationInventors: Mark R. Prausnitz, Henry F. Edelhauser, Samirkumar Rajnikant Patel
-
Publication number: 20120232522Abstract: Methods and devices are provided for targeted administration of a drug to a patient's eye. In one embodiment, the method includes inserting a hollow microneedle into the sclera of the eye at an insertion site and infusing a fluid drug formulation through the inserted microneedle and into the suprachoroidal space of the eye, wherein the infused fluid drug formulation flows within the suprachoroidal space away from the insertion site during the infusion. The fluid drug formulation may flow circumferentially toward the retinochoroidal tissue, macula, and optic nerve in the posterior segment of the eye.Type: ApplicationFiled: April 23, 2012Publication date: September 13, 2012Inventors: Mark R. Prausnitz, Henry F. Edelhauser, Samirkumar Rajnikant Patel
-
Publication number: 20120226260Abstract: Methods and devices are provided for targeted administration of a drug to a patient's eye. In one embodiment, the method includes inserting a hollow microneedle into the sclera of the eye at an insertion site and infusing a fluid drug formulation through the inserted microneedle and into the suprachoroidal space of the eye, wherein the infused fluid drug formulation flows within the suprachoroidal space away from the insertion site during the infusion. The fluid drug formulation may flow circumferentially toward the retinochoroidal tissue, macula, and optic nerve in the posterior segment of the eye.Type: ApplicationFiled: April 15, 2012Publication date: September 6, 2012Applicants: Georgia Tech Research Corporation, Emory UniversityInventors: Mark R. Prausnitz, Henry F. Edelhauser, Samirkumar Rajnikant Patel
-
Patent number: 8197435Abstract: Methods and devices are provided for targeted administration of a drug to a patient's eye. In one embodiment, the method includes inserting a hollow microneedle into the sclera of the eye at an insertion site and infusing a fluid drug formulation through the inserted microneedle and into the suprachoroidal space of the eye, wherein the infused fluid drug formulation flows within the suprachoroidal space away from the insertion site during the infusion. The fluid drug formulation may flow circumferentially toward the retinochoroidal tissue, macula, and optic nerve in the posterior segment of the eye.Type: GrantFiled: April 26, 2010Date of Patent: June 12, 2012Assignees: Emory University, Georgia Tech Research CorporationInventors: Mark R. Prausnitz, Henry F. Edelhauser, Samirkumar Rajnikant Patel
-
Patent number: 7918814Abstract: Methods and devices are provided for administering a drug to a patient's eye. The methods include (a) inserting a hollow microneedle into the sclera or corneal stroma without penetrating across the sclera or corneal stroma; and (b) infusing a fluid drug formulation through the microneedle and into the sclera or cornea. It further may include partially retracting the microneedle before infusion to enhance delivery. Alternatively, the methods may include (a) inserting a solid microneedle into the sclera or corneal stroma without penetrating across the sclera or corneal stroma, wherein the solid microneedle comprises a first quantity of a drug formulation and inserting causes the solid microneedle to form a pocket in the sclera or corneal stroma; and (b) releasing the drug formulation into the pocket to form a drug depot, whereby a drug is released from the depot. The methods and devices may include an array of multiple microneedles.Type: GrantFiled: May 2, 2007Date of Patent: April 5, 2011Assignees: Georgia Tech Research Corporation, Emory UniversityInventors: Mark R. Prausnitz, Ninghao Jiang, Henry F. Edelhauser
-
Publication number: 20100256597Abstract: Methods and devices are provided for targeted administration of a drug to a patient's eye. In one embodiment, the method includes inserting a hollow microneedle into the sclera of the eye at an insertion site and infusing a fluid drug formulation through the inserted microneedle and into the suprachoroidal space of the eye, wherein the infused fluid drug formulation flows within the suprachoroidal space away from the insertion site during the infusion. The fluid drug formulation may flow circumferentially toward the retinochoroidal tissue, macula, and optic nerve in the posterior segment of the eye.Type: ApplicationFiled: April 26, 2010Publication date: October 7, 2010Applicants: EMORY UNIVERSITY, GEORGIA TECH RESEARCH CORPORATIONInventors: Mark R. Prausnitz, Henry F. Edelhauser, Samirkumar Rajnikant Patel
-
Patent number: 4966773Abstract: Topical ophthalmic compositions containing microfine particles of one or more retinoids are described. The compositions are useful in the treatment of dry eye syndrome and related ophthalmic surface disorders and as ocular lubricants. A method of treating dry eye syndrome and related ophthalmic surface disorders and a method of providing topical ocular lubrication using these compositions are also described.Type: GrantFiled: April 17, 1989Date of Patent: October 30, 1990Assignee: Alcon Laboratories, Inc.Inventors: Philip D. Gressel, Robert E. Roehrs, John L. Ubels, Henry F. Edelhauser